These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22646267)

  • 21. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease?
    Ledder OD; Lemberg DA; Ooi CY; Day AS
    J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):583-6. PubMed ID: 23783022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
    Leong RW; Gearry RB; Sparrow MP
    Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes.
    Björnsson ES; Gu J; Kleiner DE; Chalasani N; Hayashi PH; Hoofnagle JH;
    J Clin Gastroenterol; 2017 Jan; 51(1):63-69. PubMed ID: 27648552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.
    Stocco G; Martelossi S; Barabino A; Fontana M; Lionetti P; Decorti G; Malusà N; Bartoli F; Fezzi M; Giraldi T; Ventura A
    Dig Liver Dis; 2005 Dec; 37(12):940-5. PubMed ID: 16202677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases.
    Atreya I; Diall A; Dvorsky R; Atreya R; Henninger C; Grün M; Hofmann U; Schaeffeler E; López-Posadas R; Daehn I; Zenker S; Döbrönti M; Neufert C; Billmeier U; Zundler S; Fritz G; Schwab M; Neurath MF
    J Crohns Colitis; 2016 Oct; 10(10):1132-43. PubMed ID: 27112707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization and individualization of thiopurine therapy in inflammatory bowel disease: the great variability among drug responses.
    Scherl E; Subbaramiah K
    Pharmacogenomics J; 2003; 3(2):66-8. PubMed ID: 12746731
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
    Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
    J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and histologic features of Azathioprine-induced hepatotoxicity.
    Siramolpiwat S; Sakonlaya D
    Scand J Gastroenterol; 2017 Aug; 52(8):876-880. PubMed ID: 28388864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatotoxicity of 6-mercaptopurine in Crohn's disease.
    Gross R; Scapa E
    Am J Gastroenterol; 1992 Dec; 87(12):1885-6. PubMed ID: 1449165
    [No Abstract]   [Full Text] [Related]  

  • 32. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
    Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
    Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nodular regenerative hyperplasia of the liver secondary to azathioprine in a patient with inflammatory bowel disease.
    Bryant DL; Miles CJ; Gearry RB
    N Z Med J; 2010 Apr; 123(1313):74-6. PubMed ID: 20581898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver complications in inflammatory bowel diseases.
    Wieser V; Gerner R; Moschen AR; Tilg H
    Dig Dis; 2013; 31(2):233-8. PubMed ID: 24030232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.
    Gisbert JP; Luna M; González-Lama Y; Pousa ID; Velasco M; Moreno-Otero R; Maté J
    Inflamm Bowel Dis; 2007 Sep; 13(9):1106-14. PubMed ID: 17455203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
    Seidman EG
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?
    Roberts RL; Gearry RB; Barclay ML
    Pharmacogenomics; 2010 Nov; 11(11):1505-8. PubMed ID: 21121769
    [No Abstract]   [Full Text] [Related]  

  • 39. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
    Pavlidis P; Ansari A; Duley J; Oancea I; Florin T
    Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
    Shih DQ; Nguyen M; Zheng L; Ibanez P; Mei L; Kwan LY; Bradford K; Ting C; Targan SR; Vasiliauskas EA
    Aliment Pharmacol Ther; 2012 Sep; 36(5):449-58. PubMed ID: 22784257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.